Pivot Park Screening Centre (Oss, Netherlands) has recently taken delivery of a flexible laboratory automation system from HighRes Biosolutions, forming the core of its newly implemented ultra-high-throughput screening (uHTS) facility. Pivot Park Screening Centre will use the uHTS system to perform biochemical and cell-based screening assays to support research programs across public and private partnerships.
- About Us
- The HighRes Way
- Management Team
- In the Media
- Upcoming Events
- Career Opportunities
- Contact Us
HighRes Biosolutions announced today that it will release two new products at the upcoming Society for Laboratory Automation and Screening show in Orlando in January: SampleVault, a modular automated sample store; and MicroSpin, an automated microplate centrifuge.
HighRes Biosolutions announced today that 2012 marked the greatest overall level of growth in the history of the company with respect to bookings, customer base, headcount, and facilities size. New bookings increased over 70% over 2011. In addition, customer base increased by over 40% compared with the previous year, and headcount increased by over 30%. Facilities also expanded by 70% in the US and 150% in the UK.
The Biodesign Institute® at Arizona State University has reached an agreement with HighRes Biosolutions to automate DNA sample preparation of Nucleic Acid Programmable Protein Arrays (NAPPA) using a flexible dual NanoCell™ laboratory automation system. The dual NanoCell system was selected by Dr. Joshua LaBaer, director of the Institute’s Virginia G. Piper Center For Personalized Diagnostics, and will be installed at the NAPPA core facility within his Center at Tempe, Arizona.
HighRes Biosolutions brings its robotics expertise to the world of exotic aquariums on a new episode of Animal Planet’s hit reality television series Tanked. The episode highlights the antics and excitement in designing, building, and deploying a one-of-a-kind robotic aquarium comprised of three tanks that together resemble one of HighRes’ laboratory automation systems.
The Smaller Business Association of New England (SBANE) announced that HighRes Biosolutions is a finalist for the 2012 New England Innovation Awards, which are sponsored in part by Mass High Tech and Boston Business Journal. HighRes is one of only 20 companies out of 268 nominees throughout New England to be selected.
HighRes Biosolutions has announced the release of ACell, a brand new bench top laboratory automation system that is small and safe enough for the bench top, yet flexible enough to integrate with any of HighRes' world class storage devices, and easy enough to get up and running quickly.
The Center for Genomic Science (CGS) of Istituto Italiano di Tecnologia (IIT@SEMM) based in Milan, Italy at the IFOM-IEO Campus has selected HighRes Biosolutions to supply a flexible NanoCell™ laboratory automation system. The NanoCell system will be installed in the Screening Unit of the Center and will be placed in a Biosafety Level 2+ (BSL2+) enclosure. It will automate genome-wide high-throughput and high-content siRNA screens to drive the collaborative research programs of the Center for Genomic Science of IIT@SEMM.
IRBM Science Park (Pomezia, Italy) has selected HighRes Biosolutions to supply a flexible NanoCell™ laboratory automation system. The NanoCell will be installed as IRBM updates its high-throughput screening infrastructure to support the Italian Chemical Collection and Screening Initiative, a collaboration with Italian state research institutions. The NanoCell system will automate biochemical and cell-based high-throughput screening (HTS) assays to support small-molecule drug discovery.
The David H. Koch Institute for Integrative Cancer Research at MIT has selected HighRes Biosolutions to implement modular and flexible automation for its newly implemented screening facility. HighRes will provide The Koch Institute, which is revolutionizing the diagnosis, monitoring and treatment of cancer, with two screening systems that will be linked using HighRes’ patented dockable cart-based automation platform. Investigators at the Koch Institute as well as other MIT affiliates will use the new systems for both genomic and biochemical approaches to fighting cancer with a particular interest in studying combination treatment synergies.